Drugs / Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
also known as
MenACYW-TT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04142242 | Oct 2019 → Apr 2020 | meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-04-24 | Sanofi | Regulatory FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination sanofi.com ↗
The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for MenQuadfi TM Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-04-24 | Sanofi | FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04142242 ↗ |
| Known as | MenACYW-TT | “Stage I of this study (NCT04142242) demonstrated the safety and immunogenicity of a booster dose of a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine...” PMID 39555800 ↗ Nov 2024 |
| Modality | Vaccine | “a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)” PMID 39555800 ↗ Nov 2024 |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04142242 ↗ |